- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07428447
Analyse af kutant fosforyleret alfa-synuclein til identifikation af patienter med risiko for progression fra essentiel tremor til Parkinsons sygdom (Syn-T)
Analyse af kutan fosforyleret alfa-synuklein for at identificere patienter med risiko for at udvikle sig fra essentiel tremor til Parkinsons sygdom
Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies.
Primary Objectives
- Identify which ET patients have P-SYN pathology indicative of prodromal PD
- Predict which patients are most likely to phenoconvert to PD
Studieoversigt
Status
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Jeannie Director of Clinical Research
- Telefonnummer: 371 480-434-6446
- E-mail: ClinicalResearch@cndlifesciences.com
Studiesteder
-
-
Arizona
-
Scottsdale, Arizona, Forenede Stater, 85258
- Rekruttering
- Movement Disorders Center of Arizona
-
Kontakt:
- Danica Evidente
- Telefonnummer: 480-526-5441
- E-mail: danica@movementdisorders.us
-
Ledende efterforsker:
- Virgilio Gerald H Evidente, MD
-
Scottsdale, Arizona, Forenede Stater, 85258
- Rekruttering
- CND Clinical Research Center
-
Kontakt:
- Jeannie Director of Clinical Research
- Telefonnummer: 371 480-434-6446
- E-mail: ClinicalResearch@cndlifesciences.com
-
Ledende efterforsker:
- Padma Mahant, MD
-
-
California
-
Irvine, California, Forenede Stater, 92617
- Ikke rekrutterer endnu
- University of California Irvine Health
-
Kontakt:
- Shivani Venkateswaran
- E-mail: shivanv1@uci.edu
-
Ledende efterforsker:
- Ann Ly, MD
-
Underforsker:
- Niki Maki, MD
-
Los Angeles, California, Forenede Stater, 90048
- Ikke rekrutterer endnu
- Cedars-Sinai Medical Center
-
Ledende efterforsker:
- Michele Tagliati, MD
-
Kontakt:
- Anne Tran
- Telefonnummer: 310-423-1697
- E-mail: anne.tran@cshs.org
-
Kontakt:
- Michele Lima Gregorio, PhD
- Telefonnummer: 424-315-0021
- E-mail: michele.gregorio@cshs.org
-
-
Florida
-
Orlando, Florida, Forenede Stater, 32825
- Rekruttering
- Neurology One
-
Ledende efterforsker:
- Ramon L Rodriguez, MD, FAAN
-
Kontakt:
- Jinna Santiago, RN, CRC
- Telefonnummer: 110 407-706-3060
- E-mail: jsantiago@n1research.org
-
Kontakt:
- Victor Lameda, CRC
- Telefonnummer: 109 407-706-3060
- E-mail: vlameda@n1research.org
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- Rekruttering
- University of Kansas Medical Center
-
Underforsker:
- Kelly Lyons, PhD
-
Kontakt:
- Kim Lee, Clinical Research Coordinator
- Telefonnummer: 913-588-0013
- E-mail: klee9@kumc.edu
-
Ledende efterforsker:
- Angela Richmond, MD
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40202
- Rekruttering
- Norton Healthcare
-
Kontakt:
- Andrea J Gambrell, RN, BSN, CCM
- Telefonnummer: 502-446-8544
- E-mail: andrea.gambrell@nortonhealthcare.org
-
Kontakt:
- Hannah Scully, RN
- Telefonnummer: 502-588-0719
- E-mail: hannah.scully@nortonhealthcare.org
-
Ledende efterforsker:
- Jason Crowell, MD
-
Underforsker:
- Justin Phillips, MD
-
-
Michigan
-
Farmington Hills, Michigan, Forenede Stater, 48334
- Rekruttering
- Quest Research Institute
-
Kontakt:
- Denise Morgott
- Telefonnummer: 248-957-8940
- E-mail: denise.morgott@questri.com
-
Ledende efterforsker:
- Aaron Ellenbogen, DO
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38157
- Rekruttering
- Veracity Neurosciences LLC
-
Kontakt:
- Hannah Touliatos
- Telefonnummer: 901-443-9170
- E-mail: hannah@veracityneuroscience.com
-
Ledende efterforsker:
- Mark LeDoux, MD, PhD
-
Nashville, Tennessee, Forenede Stater, 37232
- Ikke rekrutterer endnu
- Vanderbilt University Medical Center
-
Kontakt:
- Jackie Harris, RMA, CTRC IV
- Telefonnummer: 615-936-3833
- E-mail: jacqueline.c.harris@vumc.org
-
Kontakt:
- Keimora Wright, CTRC II
- Telefonnummer: 615-322-0530
- E-mail: keimora.wright@vumc.org
-
Ledende efterforsker:
- Cherrie Yu, MD
-
Underforsker:
- Amanda Currie, MD
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Baylor College of Medicine
-
Kontakt:
- Haneyeh Primary Research Coordinator
- Telefonnummer: 713-798-5120
- E-mail: haneyeh.amidi@bcm.edu
-
Kontakt:
- Rory Research Manager
- Telefonnummer: 713-798-5989
- E-mail: Rory.Mahabir@bcm.edu
-
Ledende efterforsker:
- Steven Bellows, MD
-
Underforsker:
- Karim Makhoul, MD
-
Underforsker:
- Yutong Taneff, NP
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Subjects will be enrolled from up to 18 sites across the US from academic institutions and private clinics.
Beskrivelse
Inclusion Criteria:
- Age 50-85 years old
- Diagnosis of ET as defined by the 2018 MDS Task force paper "1) isolated tremor syndrome of bilateral upper limb action tremor 2) at least 3 years' duration 3) with or without tremor in other locations (e.g., head, voice, or lower limbs) 4) absence of other neurological signs, such as dystonia, ataxia, or parkinsonism." OR
- Diagnosis of ET-Plus as stated by the 2018 MDS Task force paper, "Tremor with the characteristics of ET and additional neurological signs of uncertain significance such as impaired tandem gait, questionable dystonic posturing, memory impairment, or other mild neurologic signs of unknown significance that do not suffice to make an additional syndrome classification or diagnosis. ET with tremor at rest should be classified here."
- Willing to participate in all study procedures
- Able and willing to provide written informed consent
Exclusion Criteria:
- Under age 50, Over age 85
- Clinical evidence of severe peripheral vascular disease
- Clinically active coronary artery or cerebrovascular disease
- Participant is currently on anticoagulant or dual anti-platelet therapy
- Alcoholism
- Allergic reaction to local anesthesia
- History of or increased risk for impaired wound healing, scarring, or keloid formation
- Diagnosis of ET or ET-Plus that is clinically determined to likely be secondary to brain injury or vascular compromise
- History of other neurodegenerative disorder or evidence of neurological co-pathology
- Abnormal DaTscan
- Participant is currently receiving treatment with carbidopa-levodopa for PD
- Isolated focal tremors (head, voice)
- Task-specific tremor (e.g., primary writing tremor)
- Position-specific tremors that does not otherwise meet clinical diagnostic criteria for ET
- Sudden onset and step-wise deterioration
- Prior to enrollment, receipt of an intracranial procedure intended to treat tremor or parkinsonism, including thalamic deep brain stimulation (DBS) implantation or focused ultrasound (FUS) thalamotomy. Other prior intracranial surgery is exclusionary only when, in the investigator's or Sponsor's Chief Medical Officer's judgment, it could materially affect motor assessments, diagnostic classification, participant safety, or interpretation of study outcomes.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Essential Tremor
Those diagnosed with Essential Tremor |
|
Essential Tremor Plus
Those diagnosed with Essential Tremor Plus |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Quantity of P-SYN in skin
Tidsramme: From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24
|
Quantity of P-SYN in biopsies as a biomarker for disease progression |
From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24
|
|
Rate of Phenoconversion
Tidsramme: From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24
|
Rate of phenoconversion from Essential Tremor to Parkinson's Disease over 24 months |
From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CND-106
- R44NS143486-01 (U.S. NIH-bevilling/kontrakt)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .